Hyundai Pharmaceutical announced on June 20 that it has launched Korea’s first Parkinson's disease treatment Ropinirole hydrochloride (HCl).
The original product is global pharmaceutical company GSK's Requip tablet, and the Ropinirole drug market is worth 12 billion won based on the IQVIA data of sales in 2018.
The Hyundai Ropinirole tablet is an extended release type of medication and is more convenient to administer as it is taken once a day unlike the conventional drug, which is an immediate release (IR) type of drug that has to be administered three times a day.
Hyundai Pharmaceutical plans to accelerate the expansion of its central nervous system (CNS) business, which was launched last year. The company has been expanding its CNS product lineup by launching Mirap ER Tab. (Pramipexol ER Tab.), a Parkinson's disease treatment, for the first time in Korea.
In addition, the company plans to launch a new product containing rasagiline this year, and the CNS business is expected to expand further.